Added August 21, 2009
J Clin Oncol. 2009 Feb 20;27(6):872-7. Adjuvant chemotherapy provides significant DFS benefit, primarily by reducing the recurrence rate, within the first 2 years of adjuvant therapy with some benefit in years 3 to 4, translating into long-term OS benefit. Continue reading
Added August 21, 2009
J Clin Oncol. 2009 Jul 10;27(20):3379-84. Most patients with synchronous, stage IV CRC who receive up-front modern combination chemotherapy never require palliative surgery for their intact primary tumor. Continue reading
Added August 21, 2009
N Engl J Med. 2009 Feb 5;360(6):563-72. The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life. Continue reading
Added August 21, 2009
Ann Surg Oncol. 2009 Aug;16(8):2138-46. Concurrent resection of hepatic and EHD in well-selected patients is associated with a possibility of long-term survival. The presence of limited and resectable EHD should not be an absolute contraindication to resection. The site of EHD and the nearly universal recurrence rate must be taken into consideration. Continue reading
Added August 21, 2009
J Clin Oncol. 2009 Jul 1;27(19):3109-16. Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease. Continue reading
Added August 21, 2009
Lancet Oncol. 2009 Jan;10(1):44-52. Our trial could not rule out a difference in disease-free survival at 3 years in favour of open colectomy because the upper limit of the 95% CI for the difference just exceeded the predetermined non-inferiority boundary of 7%. However, the difference in disease-free survival between groups was small and, we believe, clinically acceptable, justifying the implementation of laparoscopic surgery into daily practice. Continue reading
Added August 29, 2008
Ann Surg Oncol. 2008 Sep;15(9):2426-32. With 90% of all events having taken place up to this time, this randomized trial shows that cytoreduction followed by HIPEC does significantly add survival time to patients affected by peritoneal carcinomatosis of colorectal origin. For a selected group, there is a possibility of long-term survival. Continue reading
Added August 21, 2008
N Engl J Med. 2008 Oct 23;359(17):1757-65. Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab. Continue reading
Added August 21, 2007
J Clin Oncol. 2007 Apr 20;25(12):1539-44. The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal. Continue reading
Added August 21, 2007
Ann Surg Oncol. 2007 Dec;14(12):3481-91. Simultaneous colorectal and minor hepatic resections are safe and should be performed for most patients with SCRLM. Due to increased risk of severe morbidity, caution should be exercised before performing simultaneous colorectal and major hepatic resections. Continue reading